ClinicalTrials.gg
RecruitingNCT05930704Updated Jul 17, 2023

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women

A Phase 1 interventional study of SHR-2017 injection and Placebo in Osteoporosis, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-07-17.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Planned enrollment
51st of 57
45 · median 120
Started
2023
with 7 others
Phase 1
11 of 87
4 open now
Primary completion
2025-04
later than 5 of 32 live
Registered
53rd of 87
by date

Among the 87 studies in Osteoporosis with a site in China, this one is the 51st largest by planned enrollment of the 57 interventional ones that give a count, is one of 8 that started in 2023, is one of 11 in phase 1, reaches primary completion later than 5 of the 32 other live ones, and was the 53rd registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

The primary objective was to evaluate the safety and tolerability of SHR-2017 after a single subcutaneous (SC) injection in postmenopausal women

03

Conditions studied

  • Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women ages ≥ 50 years.
  2. Body weight≥45 kg, (BMI) of 18.0 to 29.0 kg/m2 (inclusive).
  3. Understand in detail the content, procedure and possible adverse effects of the trial, and voluntarily sign the written form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. History of .
  2. Menopause due to simple hysterectomy.
  3. Subjects with poor blood pressure control.
  4. Subjects with positive tests for infectious diseases.
  5. Have a history of diseases related to bone metabolism.
  6. Use of drugs that may affect bone metabolism before administration.
  7. Have a history of alcoholism, medical abuse, or drug use, or have a positive alcohol breath test or drug abuse screening.
  8. Female who are pregnant or breastfeeding.
  9. Unable to tolerate venipunctures or have a history of fainting needles and blood.
  10. Other reasons that the investigator consider it inappropriate to participate in the trial.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    SHR-2017 injection

    Drug: SHR-2017 injection

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugSHR-2017 injection

    Randomized participants of multiple dose cohorts will receive a single subcutaneous dose of SHR-2017 injection.

  • DrugPlacebo

    Randomized participants will receive a single SC injection dose of matching placebo.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Time frame: From day 1 up to 9 months

Secondary outcomes

  1. Maximum observed concentration of SHR-2017 (Cmax)

    Time frame: Day 1 pre-dose up to Day 253

  2. Area under the serum concentration time curve from time 0 to time of last quantifiable serum concentration (AUC0-t) of SHR-2017

    Time frame: Day 1 pre-dose up to Day 253

  3. Time to maximum observed concentration (Tmax) of SHR-2017

    Time frame: Day 1 pre-dose up to Day 253

  4. Percent change from baseline in Urinary N-Telopeptide Corrected for Urine Creatinine (uNTx/Cr)

    Time frame: Baseline up to Day 253

  5. Percent change from baseline in serum Type I Collagen Carboxy-terminal Peptide (CTX)

    Time frame: Baseline up to Day 253

  6. Percent change from baseline in Intact Parathyroid Hormone (iPTH)

    Time frame: Baseline up to Day 253

  7. Percent change from baseline in Bone-Specific Alkaline Phosphatase (BALP)

    Time frame: Baseline up to Day 253

  8. Number of subjects who developed SHR-2017 antidrug antibodies (ADA)

    Time frame: Baseline up to Day 253

07

Study locations

1 of 1 sites recruiting
  • The First Affiliated Hospital of Shandong First Medical University
    Jinan, Shangdong 250000, China
    Recruiting
    • Wei Zhao · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Apr 2025, 21 months after the start.

Of 30 phase 1 interventional studies under Osteoporosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's planned 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2023
First posted
Jul 5, 2023
StartActual
Jul 4, 2023
Primary completionEst.
Apr 12, 2025
CompletionEst.
Apr 12, 2025
Last update
Jul 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05930704
Responsible party
Sponsor
First posted
Jul 5, 2023
Start date
Jul 4, 2023
Primary completion
Apr 12, 2025 (estimated)
Completion
Apr 12, 2025 (estimated)
Last update
Jul 17, 2023

Study contacts

Yuanyuan Huang
Contact
yuanyuan.huang@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion